Carbamazepine intravenous - Lundbeck

Drug Profile

Carbamazepine intravenous - Lundbeck

Alternative Names: Carbamazepine IV; Carbella; Carnexiv

Latest Information Update: 07 Jun 2017

Price : $50

At a glance

  • Originator OVATION Pharmaceuticals
  • Developer Lundbeck Inc
  • Class Antidepressants; Antiepileptic drugs; Antimanics; Dibenzazepines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy
  • New Molecular Entity No

Highest Development Phases

  • Registered Epilepsy

Most Recent Events

  • 22 Apr 2017 Pharmacodynamics and pharmacokinetics data from a phase I safety trial in Epilepsy presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 07 Oct 2016 Registered for Epilepsy in USA (IV)
  • 22 Apr 2016 US FDA accepts resubmission of NDA for carbamazepine intravenous for Epilepsy for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top